Epic Sciences

06.09.2016 / Chicago / GenomeWeb Back to News Listings

Epic Sciences' circulating tumor cell prostate cancer test shows promise in new JAMA study.

A new study by researchers from Memorial Sloan Kettering Cancer Center has demonstrated the predictive power of an AR-V7 protein expression test using Epic Sciences' non-EPCAM-based circulating tumor cell detection platform, which could help guide treatment decisions for men with metastatic castration-resistant prostate cancer.

Link to Genome Web story.

Learn more about the test at www.arv7.com.

Learn more about the epic sciences platform and technology.